About Denali Therapeutics Inc.
https://www.denalitherapeutics.comDenali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.
CEO
Ryan J. Watts
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 148
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
BTIG
Buy
B of A Securities
Buy
HC Wainwright & Co.
Buy
B. Riley Securities
Buy
Goldman Sachs
Buy
Wedbush
Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:13.17M
Value:$240.7M
BLACKROCK, INC.
Shares:12.29M
Value:$224.53M
VANGUARD GROUP INC
Shares:11.99M
Value:$219.11M
Summary
Showing Top 3 of 290
About Denali Therapeutics Inc.
https://www.denalitherapeutics.comDenali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $137.43M ▲ | $-126.9M ▼ | 0% | $-0.74 ▼ | $-133.57M ▼ |
| Q2-2025 | $0 | $134.96M ▼ | $-124.12M ▲ | 0% | $-0.72 ▲ | $-131.01M ▲ |
| Q1-2025 | $0 | $145.58M ▲ | $-132.97M ▼ | 0% | $-0.78 ▼ | $-142.37M ▼ |
| Q4-2024 | $0 | $129.85M ▲ | $-114.75M ▼ | 0% | $-0.67 ▼ | $-127.23M ▼ |
| Q3-2024 | $0 | $123.19M | $-107.19M | 0% | $-0.63 | $-120.92M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $848.2M ▼ | $1.06B ▼ | $129.42M ▼ | $926.2M ▼ |
| Q2-2025 | $898.95M ▲ | $1.17B ▼ | $139.19M ▼ | $1.03B ▼ |
| Q1-2025 | $817.93M ▼ | $1.27B ▼ | $148.66M ▲ | $1.12B ▼ |
| Q4-2024 | $832.33M ▼ | $1.37B ▼ | $144.5M ▲ | $1.23B ▼ |
| Q3-2024 | $836.56M | $1.45B | $135.52M | $1.32B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-126.9M ▼ | $-107.3M ▼ | $57.83M ▼ | $-778K ▼ | $-50.24M ▼ | $-105.92M ▼ |
| Q2-2025 | $-124.12M ▲ | $-75.3M ▲ | $157.94M ▲ | $1.62M ▲ | $84.26M ▲ | $-79.58M ▲ |
| Q1-2025 | $-132.97M ▼ | $-131.47M ▼ | $18.75M ▼ | $-3.76M ▲ | $-116.48M ▼ | $-136.55M ▼ |
| Q4-2024 | $-114.75M ▼ | $-83.72M ▼ | $172.21M ▲ | $-4.17M ▲ | $84.32M ▲ | $-88.81M ▼ |
| Q3-2024 | $-107.19M | $-59.14M | $93.66M | $-18.56M | $15.96M | $-63.02M |
Revenue by Products
| Product | Q3-2020 | Q4-2020 | Q1-2021 | Q2-2021 |
|---|---|---|---|---|
 Alzheimers Disease Services | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Ryan J. Watts
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 148
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
BTIG
Buy
B of A Securities
Buy
HC Wainwright & Co.
Buy
B. Riley Securities
Buy
Goldman Sachs
Buy
Wedbush
Outperform
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:13.17M
Value:$240.7M
BLACKROCK, INC.
Shares:12.29M
Value:$224.53M
VANGUARD GROUP INC
Shares:11.99M
Value:$219.11M
Summary
Showing Top 3 of 290